Invion Limited (ASX: IVX) - Share Price
Current share price for IVX : $0.034 0.003 (8.11%)+
Invion Limited (IVX) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is life-science company that is guiding the global research and development of the Photosoft technology for the treatment of a range of cancers, atherosclerosis and infectious diseases.
IVX General Information +
| ASX Code | IVX |
| Website | N/A |
| Industry/Sector | Pharmaceuticals |
| Market Cap ($M) | 3 |
| IVX Share Price | $0.034 |
| Day High | $0.035 |
| Day Low | $0.034 |
| Last Close | $0.037 |
| IVX Share Price Movement | $0.00 ( 8.11% ) |
Prices as at 16:40, 30 Oct 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Invion Limited (IVX) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Invion Limited (IVX) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Invion Limited (IVX) price-sensitive announcements
IVX - Appendix 4C and Quarterly Activities Report - September 2026
Invion Limited’s Appendix 4C and Quarterly Activities Report for the quarter ended 30 Sept
Invion Limited (IVX)
29 Oct 2026 | 9:03 AM
29 Oct 2026 | 9:03 AM
IVX - Funding Agreements Cover Up to 85% of Clinical Trials Costs
Invion Limited announced two complementary financing arrangements expected to cover up to
Invion Limited (IVX)
21 Oct 2026 | 8:52 AM
21 Oct 2026 | 8:52 AM
IVX - Recruitment Conclusion for Ph 1 NMSC Trial & Advance to Ph 2
Invion Limited announced that it has completed patient treatments and closed recruitment f
Invion Limited (IVX)
19 Oct 2026 | 10:24 AM
19 Oct 2026 | 10:24 AM
IVX - Appendix 4E and Annual Report
The annual report for Invion Limited for the financial year ending 30 June 2026 reveals a
Invion Limited (IVX)
26 Aug 2026 | 5:52 PM
26 Aug 2026 | 5:52 PM
Invion Limited (IVX) Recent ASX Announcements
IVX Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2026A | -$5.63 | -$6.30 | -48.80% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2025A | -$8.81 | -$12.20 | 39.50% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$5.63 | -$8.80 | 247.60% | 0.00 | 0.00 | 0.00% | 0.0% |
IVX Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | ||
| Clarity Pharmaceuticals Ltd (CU6) | $623M | 0.4454 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Invion Limited (IVX) | $4M | -0.4877 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Neuren Pharmaceuticals Limited (NEU) | $2,553M | -0.7857 | 0.2462 | 0.9655 | 86.5492 | 69.4483 | 35.3333 | 0.00% | 1.64% | 1.94% |
IVX Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Chiat Thian Chew | Chief Executive Officer, Executive Chairman, Executive Director | 1 Dec 2017 |
| Mr Alan Yamashita | Non-Executive Director | 12 Feb 2019 |
| Mr Paul Hilton Field | Non-Executive Director | 18 Aug 2026 |
| Ms Melanie Jaye Leydin | Non-executive director, Company Secretary | 31 Aug 2024 |
Invion Limited (IVX) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 16 Jun 2026 | CHEW, Chiat | Issued | Convertibles | 244,000 | $1.000 | $244,000.000 |
| 23 Jul 2025 | CHEW, Chiat | Issued | Options | 10,000,000 | $0.015 | $150,000.000 |
| 18 Jul 2025 | BENNALLACK, Alistair | Issued | Options | 181,064 | $0.015 | $2,715.960 |
See all changes in directors' interest & trades for Invion Limited (IVX) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
IVX Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Invion Limited (IVX). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 11,203,921 (11.55%) | Honsue Cho |
IVX Calendar of Events
| Date | Event |
|---|---|
| 25 August 2027 | Report (Annual) |
| 25 August 2027 | Report (Prelim) |
| 26 February 2027 | Report (Interim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
